Sign In
Home
Rankings
Fortune 500 India
Most Powerful Women
The Next 500
Forty Under Forty
Best B-Schools
MNC 500
Profiles
Companies
People
Business
Markets
Cryptocurrency
IPO
Stock Market
Economy
Personal Finance
Tax
Mutual Funds
Banking
Opinion
Technology
Auto
Lifestyle
Long Reads
First Edit
Ideas
Buy on Amazon
Magazine Annual Subscription
Archives
Enterprise
Investing
Macro
Infographics
Home
News
Business
Markets
Economy
Personal Finance
Opinion
Technology
Auto
Lifestyle
Media
Videos
Short Videos
Visual Stories
Magazine
July 2025
June 2025
May 2025
April 2025
March 2025
February 2025
January 2025
Rankings
Fortune 500 India
Most Powerful Women
The Next 500
Forty Under Forty
Best B-Schools
MNC 500
Profiles
Companies
People
Search
Sign In
Just In
Priya Nair to succeed Rohit Jawa as the MD and CEO of HUL, effective 1st August.
TCS records a Total Contract Value (TCV) of $9.4 billion in Q1 FY26.
“We saw robust deal closures during this quarter. We remain closely connected to our customers to help them navigate the challenges impacting their business through, among others, AI-led transformation,” K Krithivasan, CEO and MD, TCS.
“The continued global macroeconomic and geopolitical uncertainties caused a demand contraction (in the quarter),” K Krithivasan, CEO and MD, TCS.
Priya Nair to succeed Rohit Jawa as the MD and CEO of HUL, effective 1st August.
TCS records a Total Contract Value (TCV) of $9.4 billion in Q1 FY26.
“We saw robust deal closures during this quarter. We remain closely connected to our customers to help them navigate the challenges impacting their business through, among others, AI-led transformation,” K Krithivasan, CEO and MD, TCS.
“The continued global macroeconomic and geopolitical uncertainties caused a demand contraction (in the quarter),” K Krithivasan, CEO and MD, TCS.
Biosimilar
(3 search results)
Biocon Biologics gets US FDA nod for Jobevne, a biosimilar for cancer treatment
Apr 10, 2025 11:57am IST
Biocon developing 20 biosimilar products for global markets
Jan 27, 2022 9:04pm IST
Biocon wins US patent battle against Sanofi on insulin biosimilar
Dec 30, 2021 7:58pm IST
Load More